Fisher Asset Management LLC Buys 17,447 Shares of Neurocrine Biosciences, Inc. $NBIX

Fisher Asset Management LLC lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 18.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 112,242 shares of the company’s stock after acquiring an additional 17,447 shares during the quarter. Fisher Asset Management LLC owned approximately 0.11% of Neurocrine Biosciences worth $15,919,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the stock. Nilsine Partners LLC acquired a new stake in Neurocrine Biosciences during the fourth quarter worth approximately $1,197,000. Ruffer LLP acquired a new stake in Neurocrine Biosciences during the fourth quarter worth approximately $2,479,000. Korea Investment CORP grew its stake in Neurocrine Biosciences by 94.3% during the third quarter. Korea Investment CORP now owns 71,689 shares of the company’s stock worth $10,064,000 after purchasing an additional 34,800 shares during the period. Envestnet Asset Management Inc. grew its stake in Neurocrine Biosciences by 2.4% during the third quarter. Envestnet Asset Management Inc. now owns 202,846 shares of the company’s stock worth $28,476,000 after purchasing an additional 4,807 shares during the period. Finally, CIBC Private Wealth Group LLC grew its stake in Neurocrine Biosciences by 17,250.0% during the third quarter. CIBC Private Wealth Group LLC now owns 7,981 shares of the company’s stock worth $1,120,000 after purchasing an additional 7,935 shares during the period. 92.59% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on NBIX shares. Wolfe Research started coverage on Neurocrine Biosciences in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 price objective for the company. Wells Fargo & Company reduced their price objective on Neurocrine Biosciences from $180.00 to $175.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. Weiss Ratings reissued a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Tuesday, April 21st. Morgan Stanley raised their price objective on Neurocrine Biosciences from $185.00 to $191.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $185.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $185.90.

Insider Buying and Selling

In related news, Director Leslie V. Norwalk sold 3,810 shares of Neurocrine Biosciences stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $155.01, for a total transaction of $590,588.10. Following the sale, the director directly owned 2,429 shares in the company, valued at approximately $376,519.29. This trade represents a 61.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Charles Gorman sold 245,088 shares of Neurocrine Biosciences stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $154.33, for a total value of $37,824,431.04. Following the sale, the director owned 511,293 shares in the company, valued at $78,907,848.69. This trade represents a 32.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 263,898 shares of company stock worth $40,779,769. 4.60% of the stock is owned by company insiders.

Neurocrine Biosciences Stock Up 0.1%

NBIX stock opened at $155.83 on Thursday. Neurocrine Biosciences, Inc. has a twelve month low of $121.42 and a twelve month high of $162.39. The stock’s 50 day moving average is $138.29 and its 200-day moving average is $138.99. The firm has a market capitalization of $15.67 billion, a PE ratio of 24.01, a P/E/G ratio of 1.17 and a beta of 0.34.

Neurocrine Biosciences Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.